A New Era in Oncology

Our
Pioneering Approach


We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. We apply our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Learn more
helix
molecular structure

Our
ProTide Technology


We harness the power of phosphoramidate chemistry to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms and other limitations of existing nucleoside analogs.

Discover More

Our
Mission Statement


“To significantly improve the survival outcomes for patients by transforming chemotherapy and pioneering a new era in oncology”.

Hugh S. Griffith - Founder & CEO

Learn more
Hugh Griffith CEO

To Transform Chemotherapy and Pioneer a New Era in Oncology

NuCana
Biology for the Future


NuCana features on a news and current affairs style series by ITN Productions and the Royal Society of Biology (RSB).

Jigsaw pieces

Our
Leadership Team


Our highly experienced team has a successful track record of building global biopharmaceutical companies and developing new life-saving medicines for patients.

Read More

Our
Latest News


Edinburgh: July 2022

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

More News

Our
Upcoming Events


New York: June 2022

Jefferies Healthcare Conference
June 8-10, 2022

Past Events

Our
Contact Details


Global Headquarters

3 Lochside Way, Edinburgh, EH12 9DT, UK

info@nucana.com

+ 44 131 357 1111

US Office

275 Grove Street, Newton, MA 02466

info@nucana.com

+1 617 663 5708

* These fields are required.